[go: up one dir, main page]

US20150190322A1 - Composition, method and kit for enhancing hair - Google Patents

Composition, method and kit for enhancing hair Download PDF

Info

Publication number
US20150190322A1
US20150190322A1 US14/661,962 US201514661962A US2015190322A1 US 20150190322 A1 US20150190322 A1 US 20150190322A1 US 201514661962 A US201514661962 A US 201514661962A US 2015190322 A1 US2015190322 A1 US 2015190322A1
Authority
US
United States
Prior art keywords
composition
compound
hair
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/661,962
Inventor
Michael C. Brinkenhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AC PATENT HOLDING Inc
Original Assignee
AC PATENT HOLDING Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AC PATENT HOLDING Inc filed Critical AC PATENT HOLDING Inc
Priority to US14/661,962 priority Critical patent/US20150190322A1/en
Publication of US20150190322A1 publication Critical patent/US20150190322A1/en
Assigned to AC PATENT HOLDING INC. reassignment AC PATENT HOLDING INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: PHARMA PATENT HOLDING INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Definitions

  • composition Composition, method and kit for enhancing human hair including eyelashes.
  • Minoxidil 6-(1-piferidinyl)-2,4-pyrimidane-diamine 3-oxide
  • Minoxidil was originally prepared and sold for use as an antihypertensive. It was observed that, associated with the use of Minoxidil for this latter purpose, Minoxidil use also produced an increase in hair growth and thickness as reported in U.S. Pat. Nos. 4,139,619 and 4,968,812.
  • Today, Minoxidil is marketed under the trademark Rogaine® by Pfizer for the treatment of baldness on the scalp for men (alopecia androgenetica) and women.
  • finasteride Propecia®
  • Merck & Co Another example is finasteride (Propecia®), marketed by Merck & Co. Finasteride was originally developed for benign prostatic hypertrophy, and was found to be effective in the treatment of alopecia androgenetica as reported in U.S. Pat. No. 4,968,812.
  • Latanoprost is marketed by Pharmacia & Upjohn (currently a part of Pfizer) under the trademark Xalatan® for the reduction of elevated intraocular pressure in patients with glaucoma and ocular hypertension.
  • the form is a Latanoprost optical solution of 0.005% (50 ⁇ g/ml), and is applied by dropper directly onto the eye. One drop generally contains approximately 1.5 ⁇ g of Latanoprost.
  • Latanoprost has been reported to cause, in some patients, an increasing pigmentation and growth of eyelashes.
  • U.S. Pat. No. 6,262,105 stated that the use of Latanoprost leads to increased length of lashes, increased numbers of lashes along the normal lash line, increased thickness and luster of lashes, increased auxiliary lash-like terminal hair in transitional areas adjacent to areas of normal lash growth, increased lash-like terminal hairs at the medial and lateral canthal area, increased pigmentation of the lashes, increased numbers, increased length, as well as increased luster, and thickness of fine hair on the skin of the adjacent lid, and increased perpendicular angulation of lashes and lash-like terminal hairs.
  • Alcon, Inc. (“Alcon”) introduced a prostaglandin F2 ⁇ analog, commonly known as Travoprost whose chemical name is isopropyl (z)-7-[(1R, 2R, 3R, 5S)-3,5-dihydroxy-2-[(1E, 3R)-3-hydroxy-4-[( ⁇ , ⁇ , ⁇ -trifluoro-m-tolyl)oxyl]-1-butenyl]cyclopentyl]-5-heptenoate as a glaucoma treatment. Alcon also sought patent protection for Travoprost for growing hair in U.S. Patent Application No. 2003/0199590.
  • Allergan, Inc. (“Allergan”) introduced Bimatoprost whose chemical name is cyclopentane N-ethyl haptanamide-5-cis-2-(3 ⁇ -hydrosy-5-phenyl-1-trans-pentenyl)-3,5-dihydroxy,[1 ⁇ , 2 ⁇ , 3 ⁇ , 5 ⁇ ) for treating glaucoma.
  • U.S. Pat. No. 7,351,404 is directed at the use of this molecule and similar molecules for growing hair, including eyelashes. Allergan distinguishes the Bimatoprost molecule from other prostaglandins on the basis that Bimatoprost is a prostamide.
  • U.S. Pat. Nos. 5,886,035 and 5,985,920 describe fluorine containing prostaglandin derivatives for use as a preventive or therapeutic medicine for an eye disease such as glaucoma or elevated intraocular pressure.
  • FIG. 1 shows a process flow from a Corey acetate derivative to a difluoro compound that includes an ethyl amide.
  • Enhancing hair as used herein includes stimulating or promoting growth of existing hair, including stimulating or promoting a bulb or cells in a follicle associated with the formation of an actual hair into hair growth. Hair growth in this sense includes an increase in length and/or an increase in diameter of a hair. Enhancing hair also includes conditioning hair and/or cosmetically improving the appearance or beauty of the hair such that hair subject to the compound or a composition including the compound appears or feels longer, thicker and fuller. Enhancing hair also includes darkening the hair. The location of the hair includes the scalp (e.g., scalp hair), eyelid (e.g., eyelashes), and brow (e.g., eyebrows) and any other portion of human skin where hair exists or may be desired.
  • scalp hair e.g., scalp hair
  • eyelid e.g., eyelashes
  • brow e.g., eyebrows
  • a composition includes an effective hair enhancing amount of a compound represented by the following formula:
  • R and R′ are individually selected from hydrogen, or a C 1 -C 6 straight or branched chain alkyl (e.g., methyl, ethyl, isopropyl);
  • the molecule may be characterized as a difluoro prostaglandin or prostaglandin-like compound because its backbone resembles a prostaglandin.
  • a difluoro compound may be in a molecular free form (a molecule) or an acceptable salt thereof (a compound).
  • An acceptable salt is a dermatologically acceptable salt or a pharmaceutically acceptable salt.
  • An example of a salt is a hydrohalide salt of the molecule such as a hydrochloride salt.
  • the resulting salt compound will have the proton from the hydrohalide bonded to the nitrogen of the molecule and be charge balanced by the halide.
  • the compound has the following formula:
  • R, R′, X, y and x are defined above, or an acceptable salt thereof.
  • the compound is one of the following molecules or a salt thereof:
  • one or more compounds described above is/are mixed with a dermatologically compatible vehicle or carrier to form a composition.
  • Suitable vehicles include, for example, aqueous solutions such as e.g., physiological salines, oil (e.g., castor oil), solutions, foams, creams or ointments.
  • Suitable vehicles furthermore may contain dermatologically compatible preservatives such as e.g., benzalkonium chloride, surfactants like e.g., polysorbate 80, liposomes or polymers, for example, methyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone and hyaluronic acid; these may be used for increasing the viscosity.
  • dermatological compositions for topical treatment for enhancing hair that include an effective hair enhancing amount of one or more compounds as defined above and a dermatologically compatible carrier are also disclosed.
  • Effective amounts of the active compounds may be determined by one of ordinary skill in the art but will vary depending on the compound employed, frequency of application and desired result.
  • An amount of a compound or compounds will generally range from about 0.0000001 to about 10 percent, by weight, of the dermatological composition, preferably from about 0.0001 to about 10 percent, by weight, of total dermatological composition.
  • a composition may include a combination of difluoro prostaglandin or prostaglandin-like compounds described or a compound(s) and other hair treatment aids such as an antioxidant (e.g., Vitamin E), a vasodilator (e.g., minoxidil), an antimicrobial (e.g., benzoyl peroxide), or an anti-inflammatory (e.g., hydrocortisone, cyclooxygenase inhibitor, lipooxigenase inhibitor).
  • an antioxidant e.g., Vitamin E
  • a vasodilator e.g., minoxidil
  • an antimicrobial e.g., benzoyl peroxide
  • an anti-inflammatory e.g., hydrocortisone, cyclooxygenase inhibitor, lipooxigenase inhibitor.
  • the composition may be topically applied to the dermis of, for example, a human in an area desired for enhancing hair such as direct application to existing hair or the dermis in an area desired for hair enhancing as opposed to an indirect application such as to the surface of the eye.
  • a human in an area desired for enhancing hair
  • Such location may include the scalp, eyelash area or eyelid or brow of a male or female.
  • Application of the compound(s) or composition to a base of a hair or hairs may create a wicking action where the compound(s) are drawn up the length of the hair or hairs.
  • Repeated application for a sustained period of time e.g., daily for several weeks or more (e.g., one month to several months) may be desired.
  • the composition may be applied directly to the dermis where hair growth is desired.
  • This may include the scalp where, for example, a density of existing hair has been reduced due to alopecia or other mechanism (e.g., hair loss as a side effect to chemotherapy treatment).
  • alopecia or other mechanism e.g., hair loss as a side effect to chemotherapy treatment.
  • an absence of pubic hair is considered bad luck and can be a serious problem, particularly in women.
  • the composition may be applied to the pubic area to address this problem.
  • repeated daily topical application of a composition to an area of the dermis where hair growth is desired may continue until hair growth is effected and may continue periodically (daily, weekly) to maintain such growth.
  • such topical application to the dermis may, for example, utilize a delivery vehicle including the composition that is a foam or cream.
  • a composition including at least one difluoro prostaglandin or prostaglandin-like compound as described above may be applied at the base of an eyelid adjacent to or where hair grows from the follicles (e.g., along the lash line).
  • the composition may be applied to the eyelashes themselves. Repeated application for consecutive days, weeks or months (e.g., regular daily application for six months) of the composition to eyelashes or areas of eyelid dermis associated with eyelashes (e.g., the base of an eyelid containing follicles in which eyelashes grow) will condition and cosmetically enhance existing eyelashes such that the eyelashes appear longer, thicker and fuller. Such application will also stimulate or promote the growth of eyelashes.
  • a kit in another embodiment, may include the composition of at least one difluoro prostaglandin or prostaglandin-like compound as described above in a dermatologically compatible vehicle or carrier in a container.
  • the container includes an amount of the composition for repeated application over a period, such as enough of the composition for daily application over a period of six months.
  • the container may also include an applicator, such as a mascara brush or other instrument for application of the composition to skin.
  • the container may be pressurized and include a nozzle to dispense a desired amount onto the hand of a user.
  • an omega chain backbone such as dimethyl 2-oxo-3-phenoxy-propyl phosphonate is added via an exchange reaction.
  • the oxo group in the 2 position is preserved in the formed intermediate and then reduced with a fluorine compound to produce a difluoro precursor.
  • the alpha chain is added at another site of the Corey acetate derivative yielding 3,3-difluoro-4-phenoxybut-1-enyl-3,5 -dihydroxycyclopentyl-hept-5-enoic acid.
  • FIG. 1 shows a process flow from a Corey acetate derivative to the acid, to the ester and then to an ethyl amide (Compound 3).
  • U.S. Pat. No. 5,886,035 also describes a method of preparing difluoro-prostaglandin derivatives but does not describe the use of such derivatives in hair (eyelash) growth.
  • compositions for topical application and methods of topical application of a composition to modify hair are described wherein the modification includes increased curl of hair on a subject or hair that is not biologically attached to or is not naturally a part of a subject (e.g., hair of a wig or extension) (“non-natural hair”).
  • the modification includes increased curl of the hair together with conditioning hair and/or cosmetically improving the appearance or beauty of the hair (e.g., increased look and feel of softness and silkiness).
  • the compositions described may be applied to existing hair on the scalp or eyelashes or non-natural hair to increase the curl and/or the look and feel of the hair.
  • a composition includes an effective amount of a compound represented by the following formula:
  • dashed bonds represent a single or double bond and when a bond in either chain is a double bond, cis or trans configuration is contemplated;
  • a and B are individually selected from a hydrogen atom, a hydroxyl group (—OH) and a halogen atom (e.g., a fluorine atom), with the proviso that when one of A and B is a hydroxyl group, the other of A and B is a hydrogen atom and when one of A and B is a halogen atom, the other of A and B is a halogen atom or a hydrogen atom;
  • Z is a cycloalkyl moiety having from three to seven carbon atoms, an aryl moiety including from four to ten carbon atoms or a heteroaryl moiety including three to nine carbon atoms and at least one heteroatom selected from nitrogen, oxygen and sulfur; and
  • X 1 and X 2 are individually selected from a hydrogen atom, an alkyl moiety having from one to six carbon atoms,
  • R 5 is an alkyl moiety having from one to six carbon atoms
  • the compound may be in free form (a molecule) or an acceptable salt thereof (a compound) such as a cationic or anionic salt formed at the nitrogen atom of the molecule, in association with a carrier adapted for topical application to mammalian skin.
  • a compound such as a cationic or anionic salt formed at the nitrogen atom of the molecule, in association with a carrier adapted for topical application to mammalian skin.
  • reference to a compound will include a molecule or a compound.
  • the compound is represented by the following formula:
  • Y is selected from an alkyl group, a halogen atom (e.g., fluorine, chlorine), a nitro group, an amino group, a thiol group, a hydroxy group, an alkyloxy group, an alkylcarboxy group, a halo substituted alkyl wherein the alkyl includes from one to six carbon atoms, and n is 0 or an integer of from 1 to 3, or an acceptable salt thereof.
  • a halogen atom e.g., fluorine, chlorine
  • the compound has the following formula:
  • A, B, X 1 , X 2 , Y and n are as defined above, or an acceptable salt thereof.
  • the compound is selected from any of compounds (1)-(5) above or a molecule having one of the following formulas or a salt thereof:
  • Compounds (6)-(9) may be prepared using techniques known in the art including, for example, techniques described in U.S. Pat. Nos. 5,001,153; 5,422,368; 5,510,383; and 5,607,978.
  • the one or more compounds described above is/are mixed with a dermatologically compatible vehicle or carrier.
  • Suitable vehicles include, for example, aqueous solutions such as e.g., physiological salines, oil (e.g., castor oil), water solutions, water/alcohol solutions or ointments.
  • Suitable vehicles furthermore may contain dermatologically compatible preservatives such as e.g., benzalkonium chloride, surfactants like e.g., polysorbate 80, liposomes or polymers, for example, methyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone and hyaluronic acid; these may be used for increasing the viscosity.
  • dermatological compositions for topical treatment for inducing or stimulating modification of existing hair including increased curl which include an effective hair modifying amount of one or more compounds as defined above and a dermatologically compatible carrier are also disclosed wherein the modification includes increased curl of hair or increased curl.
  • Effective amounts of the compound may be determined by one of ordinary skill in the art but will vary depending on the compound employed, frequency of application and desired result, and the compound will generally range from about 0.0000001 to about 50%, by weight, of the dermatological composition, preferably from about 0.001 to about 50%, by weight, of total dermatological composition, more preferably from about 0.1 to about 30%, by weight of the composition.
  • a composition may include a combination of compounds described or a compound(s) and other hair treatment aids such as an antioxidant (e.g., Vitamin E), a vasodilator (e.g., minoxidil), an antimicrobial (e.g., benzoyl peroxide), or an anti-inflammatory (e.g., hydrocortisone, cyclooxygenase inhibitor, lipooxigenase inhibitor).
  • an antioxidant e.g., Vitamin E
  • a vasodilator e.g., minoxidil
  • an antimicrobial e.g., benzoyl peroxide
  • an anti-inflammatory e.g., hydrocortisone, cyclooxygenase inhibitor, lipooxigenase inhibitor.
  • the composition may be topically applied to existing hair and retained on the hair. Such location may include the scalp or eyelash area of a male or female. Repeated application for a sustained period of time (e.g., daily for several weeks or more (e.g., one month to several months)) may be desired.
  • the composition may be beneficial to persons that naturally have straight scalp hair to aid in the curl of such hair.
  • Evidence of the effectiveness of a composition of compound (3) (dechloro-dihydroxy-difluoro-ethylcloprostenate) and, alternatively, of compound (8) (trifluoromethyl dechloroethyl prostenolamide) in application to generally straight Asian hair indicates a profound curling effect.
  • the composition is suitable for modifying eyelashes.
  • a composition would be provided to a subject with instructions on use (e.g., by instructions on or with a kit, the kit including the composition and the instructions). The subject would be instructed to apply the composition to eyelash hair.
  • modifying the eyelashes e.g., increasing the curl and/or look and feel
  • it is anticipated that application to a hair follicle will increase the thickness (e.g., diameter) of the follicle.
  • the composition may be topically applied to hair on the scalp.
  • a subject interested in establishing a curl to a portion of the subject's scalp hair or improving a natural curl would be instructed (e.g., by instructions on or with a kit) to topically apply the composition to the desired portion of the hair and to leave the composition on the hair.
  • a period of time e.g., days, weeks
  • the subject would be instructed to repeat the application for a period ranging from days to weeks.
  • the applications described above may be used to modify non-natural hair (e.g., hair not biologically attached to or is not naturally a part of a subject).
  • non-natural hair e.g., hair not biologically attached to or is not naturally a part of a subject.
  • hair include, but are not limited to, wigs and hair extensions.
  • a kit in another embodiment, may include the composition of at least one compound having the formula III or IV as described above in a dermatologically compatible vehicle or carrier in a container.
  • the container includes an amount of the composition for repeated application over a period, such as enough of the composition for daily application over a period of six months.
  • the container may also include an applicator, such as a mascara brush or other instrument for application of the composition to skin.
  • an applicator such as a mascara brush or other instrument for application of the composition to skin.
  • the container may be pressurized and include a nozzle to dispense a desired amount onto the hand of a user.
  • TDP trifluoromethyl dechloroethyl prostenolamide
  • a solution of TDP was prepared including 97.6 percent water, 0.24 percent TDP and 2.16 percent ethyl alcohol.
  • Samples of human hair separated from a subject were treated with water alone while others were treated with the TDP solution.
  • the treatment involved dipping the dry hair samples into the water and TDP solutions to one minute.
  • the hair treated with water alone did not show similar curl.
  • the results are illustrated in FIG. 1 .
  • the hair treated with the TDP solution had a noticeable and palpable increase in the look and feel of softness and silkiness compared to the hair treated with the water alone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions for application and methods of application of a composition to modify hair. In one embodiment, a composition includes a compound (molecule) represented by:
Figure US20150190322A1-20150709-C00001
    • wherein A and B are individually selected from a hydrogen, a hydroxyl group and a halogen, with the proviso that when one of A and B is a hydroxyl group, the other of A and B is a hydrogen and when one of A and B is a halogen, the other of A and B is a halogen or a hydrogen;
    • wherein Z is, for example, an aryl moiety; and
    • wherein X1 and X2 are, for example, individually selected from a hydrogen and an alkyl moiety,
    • wherein R1 and R2 are individually selected from an oxo, a hydroxyl or an ester group;
    • wherein y is 0 or 1, x is 0 or 1 and x and y are not both 1, or a salt.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • The application is a divisional application of co-pending U.S. patent application Ser. No. 13/631,193, filed Sep. 28, 2012, which is a continuation of co-pending U.S. patent application Ser. No. 12/698,823, filed Feb. 2, 2010, which claims the benefit of the earlier filing date of co-pending U.S. Provisional Patent Application No. 61/149,661, filed Feb. 3, 2009 and incorporated herein by reference.
    • FIELD
  • Composition, method and kit for enhancing human hair including eyelashes.
    • BACKGROUND
  • Certain therapeutic agents have been known to induce hair growth. One example is Minoxidil, 6-(1-piferidinyl)-2,4-pyrimidane-diamine 3-oxide (U.S. Pat. Nos. 3,382,247 and 3,644,363). Minoxidil was originally prepared and sold for use as an antihypertensive. It was observed that, associated with the use of Minoxidil for this latter purpose, Minoxidil use also produced an increase in hair growth and thickness as reported in U.S. Pat. Nos. 4,139,619 and 4,968,812. Today, Minoxidil is marketed under the trademark Rogaine® by Pfizer for the treatment of baldness on the scalp for men (alopecia androgenetica) and women. Another example is finasteride (Propecia®), marketed by Merck & Co. Finasteride was originally developed for benign prostatic hypertrophy, and was found to be effective in the treatment of alopecia androgenetica as reported in U.S. Pat. No. 4,968,812.
  • Among the drugs introduced for lowering intraocular pressure are molecules of the family prostaglandin F2. The Upjohn Company identified a prostaglandin F2α a analog, commonly known as Latanoprost and whose chemical name is isopropyl-(Z)-7[(1R, 2R, 3R, 5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylp-entyl]cyclopentyl]-5-heptenoate. Latanoprost is marketed by Pharmacia & Upjohn (currently a part of Pfizer) under the trademark Xalatan® for the reduction of elevated intraocular pressure in patients with glaucoma and ocular hypertension. The form is a Latanoprost optical solution of 0.005% (50 μg/ml), and is applied by dropper directly onto the eye. One drop generally contains approximately 1.5 μg of Latanoprost.
  • In the course of its use for reduction of intraocular pressure, Latanoprost has been reported to cause, in some patients, an increasing pigmentation and growth of eyelashes. U.S. Pat. No. 6,262,105 stated that the use of Latanoprost leads to increased length of lashes, increased numbers of lashes along the normal lash line, increased thickness and luster of lashes, increased auxiliary lash-like terminal hair in transitional areas adjacent to areas of normal lash growth, increased lash-like terminal hairs at the medial and lateral canthal area, increased pigmentation of the lashes, increased numbers, increased length, as well as increased luster, and thickness of fine hair on the skin of the adjacent lid, and increased perpendicular angulation of lashes and lash-like terminal hairs.
  • Alcon, Inc. (“Alcon”) introduced a prostaglandin F2α analog, commonly known as Travoprost whose chemical name is isopropyl (z)-7-[(1R, 2R, 3R, 5S)-3,5-dihydroxy-2-[(1E, 3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxyl]-1-butenyl]cyclopentyl]-5-heptenoate as a glaucoma treatment. Alcon also sought patent protection for Travoprost for growing hair in U.S. Patent Application No. 2003/0199590.
  • Allergan, Inc. (“Allergan”) introduced Bimatoprost whose chemical name is cyclopentane N-ethyl haptanamide-5-cis-2-(3α-hydrosy-5-phenyl-1-trans-pentenyl)-3,5-dihydroxy,[1α, 2α, 3α, 5α) for treating glaucoma. U.S. Pat. No. 7,351,404 is directed at the use of this molecule and similar molecules for growing hair, including eyelashes. Allergan distinguishes the Bimatoprost molecule from other prostaglandins on the basis that Bimatoprost is a prostamide.
  • U.S. Pat. Nos. 5,886,035 and 5,985,920 describe fluorine containing prostaglandin derivatives for use as a preventive or therapeutic medicine for an eye disease such as glaucoma or elevated intraocular pressure.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows a process flow from a Corey acetate derivative to a difluoro compound that includes an ethyl amide.
    •  DETAILED DESCRIPTION
  • Compositions for topical application, methods of topical application of a composition to enhance hair, and a kit are described. Enhancing hair as used herein includes stimulating or promoting growth of existing hair, including stimulating or promoting a bulb or cells in a follicle associated with the formation of an actual hair into hair growth. Hair growth in this sense includes an increase in length and/or an increase in diameter of a hair. Enhancing hair also includes conditioning hair and/or cosmetically improving the appearance or beauty of the hair such that hair subject to the compound or a composition including the compound appears or feels longer, thicker and fuller. Enhancing hair also includes darkening the hair. The location of the hair includes the scalp (e.g., scalp hair), eyelid (e.g., eyelashes), and brow (e.g., eyebrows) and any other portion of human skin where hair exists or may be desired.
  • In one embodiment, a composition includes an effective hair enhancing amount of a compound represented by the following formula:
  • Figure US20150190322A1-20150709-C00002
  • wherein the dashed bonds represent a single or double bond that can be in the cis or trans configuration; R and R′ are individually selected from hydrogen, or a C1-C6 straight or branched chain alkyl (e.g., methyl, ethyl, isopropyl); X is a halide (e.g., F, Cl, Br, I) a halide-containing group (e.g., CF3), or hydrogen; either y=0 and x=1 or y=1 and x=0. The molecule may be characterized as a difluoro prostaglandin or prostaglandin-like compound because its backbone resembles a prostaglandin.
  • A difluoro compound may be in a molecular free form (a molecule) or an acceptable salt thereof (a compound). An acceptable salt is a dermatologically acceptable salt or a pharmaceutically acceptable salt. An example of a salt is a hydrohalide salt of the molecule such as a hydrochloride salt. In one embodiment, the resulting salt compound will have the proton from the hydrohalide bonded to the nitrogen of the molecule and be charge balanced by the halide. Throughout this description, unless specifically indicated a reference to a compound includes a molecule or a compound.
  • In another embodiment, the compound has the following formula:
  • Figure US20150190322A1-20150709-C00003
  • wherein R, R′, X, y and x are defined above, or an acceptable salt thereof.
  • In a particular embodiment, the compound is one of the following molecules or a salt thereof:
  • Figure US20150190322A1-20150709-C00004
  • Figure US20150190322A1-20150709-C00005
  • In one embodiment, one or more compounds described above is/are mixed with a dermatologically compatible vehicle or carrier to form a composition. Suitable vehicles include, for example, aqueous solutions such as e.g., physiological salines, oil (e.g., castor oil), solutions, foams, creams or ointments. Suitable vehicles furthermore may contain dermatologically compatible preservatives such as e.g., benzalkonium chloride, surfactants like e.g., polysorbate 80, liposomes or polymers, for example, methyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone and hyaluronic acid; these may be used for increasing the viscosity.
  • In one embodiment, dermatological compositions for topical treatment for enhancing hair that include an effective hair enhancing amount of one or more compounds as defined above and a dermatologically compatible carrier are also disclosed. Effective amounts of the active compounds may be determined by one of ordinary skill in the art but will vary depending on the compound employed, frequency of application and desired result. An amount of a compound or compounds will generally range from about 0.0000001 to about 10 percent, by weight, of the dermatological composition, preferably from about 0.0001 to about 10 percent, by weight, of total dermatological composition.
  • In another embodiment, a composition may include a combination of difluoro prostaglandin or prostaglandin-like compounds described or a compound(s) and other hair treatment aids such as an antioxidant (e.g., Vitamin E), a vasodilator (e.g., minoxidil), an antimicrobial (e.g., benzoyl peroxide), or an anti-inflammatory (e.g., hydrocortisone, cyclooxygenase inhibitor, lipooxigenase inhibitor).
  • The composition may be topically applied to the dermis of, for example, a human in an area desired for enhancing hair such as direct application to existing hair or the dermis in an area desired for hair enhancing as opposed to an indirect application such as to the surface of the eye. Such location may include the scalp, eyelash area or eyelid or brow of a male or female. Application of the compound(s) or composition to a base of a hair or hairs may create a wicking action where the compound(s) are drawn up the length of the hair or hairs. Repeated application for a sustained period of time (e.g., daily for several weeks or more (e.g., one month to several months)) may be desired.
  • Where hair is not present, the composition may be applied directly to the dermis where hair growth is desired. This may include the scalp where, for example, a density of existing hair has been reduced due to alopecia or other mechanism (e.g., hair loss as a side effect to chemotherapy treatment). In certain Asian cultures, an absence of pubic hair is considered bad luck and can be a serious problem, particularly in women. The composition may be applied to the pubic area to address this problem. In one embodiment, repeated daily topical application of a composition to an area of the dermis where hair growth is desired may continue until hair growth is effected and may continue periodically (daily, weekly) to maintain such growth. In one embodiment, such topical application to the dermis may, for example, utilize a delivery vehicle including the composition that is a foam or cream.
  • To enhance eyelashes, a composition including at least one difluoro prostaglandin or prostaglandin-like compound as described above may be applied at the base of an eyelid adjacent to or where hair grows from the follicles (e.g., along the lash line). Alternatively or additionally, the composition may be applied to the eyelashes themselves. Repeated application for consecutive days, weeks or months (e.g., regular daily application for six months) of the composition to eyelashes or areas of eyelid dermis associated with eyelashes (e.g., the base of an eyelid containing follicles in which eyelashes grow) will condition and cosmetically enhance existing eyelashes such that the eyelashes appear longer, thicker and fuller. Such application will also stimulate or promote the growth of eyelashes.
  • In another embodiment, a kit is disclosed. The kit may include the composition of at least one difluoro prostaglandin or prostaglandin-like compound as described above in a dermatologically compatible vehicle or carrier in a container. The container includes an amount of the composition for repeated application over a period, such as enough of the composition for daily application over a period of six months. The container may also include an applicator, such as a mascara brush or other instrument for application of the composition to skin. In the case of a composition in the form of a foam, the container may be pressurized and include a nozzle to dispense a desired amount onto the hand of a user.
    • EXAMPLE 1 Synthesis of 3,3-difluoro-4-phenoxybut-l-enyl-3,5-dihydroxycyclopentyl-hept-5-enoic acid
  • Starting from a Corey acetate derivative, an omega chain backbone, such as dimethyl 2-oxo-3-phenoxy-propyl phosphonate is added via an exchange reaction. The oxo group in the 2 position is preserved in the formed intermediate and then reduced with a fluorine compound to produce a difluoro precursor. Subsequently, the alpha chain is added at another site of the Corey acetate derivative yielding 3,3-difluoro-4-phenoxybut-1-enyl-3,5 -dihydroxycyclopentyl-hept-5-enoic acid.
  • Figure US20150190322A1-20150709-C00006
    • EXAMPLE 2 Synthesis of 3,3-difluoro-4-phenoxybut-l-enyl-3,5-dihydroxycyclopentyl-menthylhept-5-enoate
  • To the 3,3 -difluoro-4-phenoxybut-1-enyl-3,5-dihydroxycyclopentyl-hept-5-enoic acid is added iodomethane in a solution of tetrahydroturan (THF) to form 3,3-difluoro-4-phenoxybut-1-enyl-3,5-dihydroxycyclopentyl-methylhept-5-enoate.
  • Figure US20150190322A1-20150709-C00007
    • EXAMPLE 3 Synthesis of 3,3-difluoro-4-phenoxybut-l-enyl-3,5-dihydroxycyclopentyl-N-ethylhept-5-enamide
  • To the 3,3-difluoro-4-phenoxybut-l-enyl-3,5-dihydroxycyclopentyl-methylhept-5-enoate is added ethylamine in water to form 3,3-difluoro-4-phenoxybut-1-enyl-3,5-dihydroxycyclopentyl-N-ethylhept-5-enamide.
  • Figure US20150190322A1-20150709-C00008
  • FIG. 1 shows a process flow from a Corey acetate derivative to the acid, to the ester and then to an ethyl amide (Compound 3). U.S. Pat. No. 5,886,035 also describes a method of preparing difluoro-prostaglandin derivatives but does not describe the use of such derivatives in hair (eyelash) growth.
  • The following examples provide representative compositions including a difluoro compound such as Compound 3:
    • EXAMPLE 4 Eyelash Composition
  • Ingredient Percentage
     1. Water (Aqua) 97.791
     2. Sodium Chloride 0.877
     3. Panthenol 0.020
     4. Citric Acid 0.030
     5. Phenoxyethanol 0.300
     6. Chlohenesin 0.300
     7. Disodium Phosphate 0.142
     8. Difluoro Compound 0.024
     9. Alcohol 0.216
    10. Cellulose Gum 0.300
    • EXAMPLE 5 Eyelash Composition
  • Ingredient Percentage
     1. USP Water 94.519
     2. Sodium Chloride 0.077
     3. Phosphoric Acid 0.03
     4. Phenoxyethanol 0.3
     5. Chlorphenesin 0.3
     6. Disodium Phosphate 0.142
     7. Cellulose Gum 0.36
     8. Biotin 0.5
     9. Glycerin 0.6
    10. Swertia Japonica Extract 0.045
    11. Saw Palmetto Extract 0.064
    12. Camellia Sinensis (White 0.054
      Tea) Leaf Extract
    13. Panax Ginseng 0.075
    14. Octapeptide-2 0.93
    15. Biotinoyl Tripeptide-1 0.93
    16. Wheat Protein 0.25
    17. Calendula 0.8
    18. Difluoro Compound 0.024
    • EXAMPLE 6 Eyelash Composition
  • Ingredient Percentage
     1. USP Water 96.031
     2. Actiphyte of Rosemary 0.025
     3. Phosphoric Acid 0.001
     4. Phenoxyethanol 0.3
     5. Chlorphenesin 0.3
     6. Disodium Phosphate 0.985
     7. Cellulose Gum 0.36
     8. Biotin 0.24
     9. Panthenol 0.25
    10. Actiphyte of Nettles 0.1
    11. Actiphyte of Horsetail 0.098
    12. Actiphyte of Psoralea Seed 0.15
    13. Mulberry Root Extract 0.07
    14. Actiphyte of Japanese Green Tea 0.25
    15. Glycerin 0.6
    16. Difluoro Compound (in 10% 0.24
      Ethanol Solution)
    • EXAMPLE 7 Scalp Composition
  • Ingredient Percentage
     1. Water 95.00000
     2. Acrylates Copolymer  1.50000
     3. Glycerin  1.00000
     4. Phenoxyethanol  0.80000
     5. Sodium Cocoyl Glutamate  0.35000
     6. Chlorphenesin  0.30000
     7. Polysorbate  0.25000
     8. Trifluoromethyl Dechloro  0.24000
      Ethylprostenolamide
     9. Disodium EDTA 0.10000
    10. Fragrance 0.09610
    11. Aminomethyl Propanol 0.09000
    12. Panax Ginseng Root Extract 0.08000
    13. Panthenol 0.08000
    14. Ginko Bilola Leaf Extract 0.05000
    15. Biotin 0.05000
    16. Serenoa Serrulata Fruit Extract 0.00640
    17. Swertia Japonica Extract 0.00450
    18. Hydrolyzed Wheat Protein 0.00300
  • In another embodiment, compositions for topical application and methods of topical application of a composition to modify hair are described wherein the modification includes increased curl of hair on a subject or hair that is not biologically attached to or is not naturally a part of a subject (e.g., hair of a wig or extension) (“non-natural hair”). In another embodiment, the modification includes increased curl of the hair together with conditioning hair and/or cosmetically improving the appearance or beauty of the hair (e.g., increased look and feel of softness and silkiness). Thus, the compositions described may be applied to existing hair on the scalp or eyelashes or non-natural hair to increase the curl and/or the look and feel of the hair. In one embodiment, a composition includes an effective amount of a compound represented by the following formula:
  • Figure US20150190322A1-20150709-C00009
  • wherein the dashed bonds represent a single or double bond and when a bond in either chain is a double bond, cis or trans configuration is contemplated;
  • wherein A and B are individually selected from a hydrogen atom, a hydroxyl group (—OH) and a halogen atom (e.g., a fluorine atom), with the proviso that when one of A and B is a hydroxyl group, the other of A and B is a hydrogen atom and when one of A and B is a halogen atom, the other of A and B is a halogen atom or a hydrogen atom;
  • wherein Z is a cycloalkyl moiety having from three to seven carbon atoms, an aryl moiety including from four to ten carbon atoms or a heteroaryl moiety including three to nine carbon atoms and at least one heteroatom selected from nitrogen, oxygen and sulfur; and
  • wherein X1 and X2 are individually selected from a hydrogen atom, an alkyl moiety having from one to six carbon atoms,
  • Figure US20150190322A1-20150709-C00010
  • and
  • R5 is an alkyl moiety having from one to six carbon atoms;
  • wherein R1 and R2 are individually selected from an oxo group (=O), a hydroxyl group (—OH) or an ester group (—O(CO)R6), and R6 is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, and —(CH2)mR7 wherein m is 0 or an integer of from 1 to 10, and R7 is cycloalkyl group, having from three to seven carbon atoms, or an aryl or heteroaryl group, as defined above;
  • wherein y is 0 or 1, x is 0 or 1 and x and y are not both 1.
  • The compound may be in free form (a molecule) or an acceptable salt thereof (a compound) such as a cationic or anionic salt formed at the nitrogen atom of the molecule, in association with a carrier adapted for topical application to mammalian skin. Unless specified, reference to a compound will include a molecule or a compound.
  • In one embodiment, the compound is represented by the following formula:
  • Figure US20150190322A1-20150709-C00011
  • wherein Y is selected from an alkyl group, a halogen atom (e.g., fluorine, chlorine), a nitro group, an amino group, a thiol group, a hydroxy group, an alkyloxy group, an alkylcarboxy group, a halo substituted alkyl wherein the alkyl includes from one to six carbon atoms, and n is 0 or an integer of from 1 to 3, or an acceptable salt thereof.
  • In another embodiment, the compound has the following formula:
  • Figure US20150190322A1-20150709-C00012
  • wherein A, B, X1, X2, Y and n are as defined above, or an acceptable salt thereof.
  • In a particular embodiment, the compound is selected from any of compounds (1)-(5) above or a molecule having one of the following formulas or a salt thereof:
  • Figure US20150190322A1-20150709-C00013
  • Compounds (6)-(9) may be prepared using techniques known in the art including, for example, techniques described in U.S. Pat. Nos. 5,001,153; 5,422,368; 5,510,383; and 5,607,978.
  • In one embodiment, the one or more compounds described above (including compounds (1)-(9) is/are mixed with a dermatologically compatible vehicle or carrier. Suitable vehicles include, for example, aqueous solutions such as e.g., physiological salines, oil (e.g., castor oil), water solutions, water/alcohol solutions or ointments. Suitable vehicles furthermore may contain dermatologically compatible preservatives such as e.g., benzalkonium chloride, surfactants like e.g., polysorbate 80, liposomes or polymers, for example, methyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone and hyaluronic acid; these may be used for increasing the viscosity.
  • In one embodiment, dermatological compositions for topical treatment for inducing or stimulating modification of existing hair including increased curl which include an effective hair modifying amount of one or more compounds as defined above and a dermatologically compatible carrier are also disclosed wherein the modification includes increased curl of hair or increased curl. Effective amounts of the compound may be determined by one of ordinary skill in the art but will vary depending on the compound employed, frequency of application and desired result, and the compound will generally range from about 0.0000001 to about 50%, by weight, of the dermatological composition, preferably from about 0.001 to about 50%, by weight, of total dermatological composition, more preferably from about 0.1 to about 30%, by weight of the composition. In another embodiment, a composition may include a combination of compounds described or a compound(s) and other hair treatment aids such as an antioxidant (e.g., Vitamin E), a vasodilator (e.g., minoxidil), an antimicrobial (e.g., benzoyl peroxide), or an anti-inflammatory (e.g., hydrocortisone, cyclooxygenase inhibitor, lipooxigenase inhibitor).
  • The composition may be topically applied to existing hair and retained on the hair. Such location may include the scalp or eyelash area of a male or female. Repeated application for a sustained period of time (e.g., daily for several weeks or more (e.g., one month to several months)) may be desired. The composition may be beneficial to persons that naturally have straight scalp hair to aid in the curl of such hair. Evidence of the effectiveness of a composition of compound (3) (dechloro-dihydroxy-difluoro-ethylcloprostenate) and, alternatively, of compound (8) (trifluoromethyl dechloroethyl prostenolamide) in application to generally straight Asian hair indicates a profound curling effect.
  • In one embodiment, the composition is suitable for modifying eyelashes. To modify eyelashes, a composition would be provided to a subject with instructions on use (e.g., by instructions on or with a kit, the kit including the composition and the instructions). The subject would be instructed to apply the composition to eyelash hair. In addition to modifying the eyelashes (e.g., increasing the curl and/or look and feel), it is anticipated that application to a hair follicle will increase the thickness (e.g., diameter) of the follicle.
  • In one embodiment, the composition may be topically applied to hair on the scalp. For example, a subject interested in establishing a curl to a portion of the subject's scalp hair or improving a natural curl, would be instructed (e.g., by instructions on or with a kit) to topically apply the composition to the desired portion of the hair and to leave the composition on the hair. To improve or sustain the curl over a period of time (e.g., days, weeks), the subject would be instructed to repeat the application for a period ranging from days to weeks.
  • In another embodiment, the applications described above may be used to modify non-natural hair (e.g., hair not biologically attached to or is not naturally a part of a subject). Examples of such hair include, but are not limited to, wigs and hair extensions.
  • In another embodiment, a kit is disclosed. The kit may include the composition of at least one compound having the formula III or IV as described above in a dermatologically compatible vehicle or carrier in a container. The container includes an amount of the composition for repeated application over a period, such as enough of the composition for daily application over a period of six months. The container may also include an applicator, such as a mascara brush or other instrument for application of the composition to skin. In the case of a composition in the form of a foam, the container may be pressurized and include a nozzle to dispense a desired amount onto the hand of a user.
    • EXAMPLE
  • The following example used trifluoromethyl dechloroethyl prostenolamide (TDP) as a compound. TDP has the following formula:
  • Figure US20150190322A1-20150709-C00014
  • A solution of TDP was prepared including 97.6 percent water, 0.24 percent TDP and 2.16 percent ethyl alcohol. Samples of human hair separated from a subject were treated with water alone while others were treated with the TDP solution. The treatment involved dipping the dry hair samples into the water and TDP solutions to one minute. Unexpectedly, there appeared a definite increase in curl in each of the hair samples when treated with the TDP solution. The hair treated with water alone did not show similar curl. The results are illustrated in FIG. 1. In addition, the hair treated with the TDP solution had a noticeable and palpable increase in the look and feel of softness and silkiness compared to the hair treated with the water alone.
  • In the preceding detailed description, reference is made to specific embodiments thereof. It will, however, be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the following claims. The specification and drawings are, accordingly, to be regarded in an illustrative rather than a restrictive sense.

Claims (17)

What is claimed is:
1. A composition comprising a compound of the formula:
Figure US20150190322A1-20150709-C00015
wherein the dashed bonds represent a single or double bond; R and R′ are individually selected from the group consisting of hydrogen, a C1-C6 straight or branched chain alkyl; X is selected from the group consisting of a halide, a halide containing group or a hydrogen; y is 0 or 1, x is 0 or 1 and x and y are not both 1 or not both 0; or a salt thereof.
2. A composition of claim 1, wherein the compound has the formula:
Figure US20150190322A1-20150709-C00016
3. A composition of claim 2, wherein the compound has the formula:
Figure US20150190322A1-20150709-C00017
4. A composition of claim 2, wherein the compound has the formula:
Figure US20150190322A1-20150709-C00018
5. A composition of claim 2, wherein the compound has the formula:
Figure US20150190322A1-20150709-C00019
6. A composition of claim 2, wherein the compound has the formula:
Figure US20150190322A1-20150709-C00020
7. The composition of claim 1, further comprising a dermatologically acceptable carrier.
8. A method comprising:
directly applying to dermis or hair on the dermis an amount of a composition comprising a compound of the formula:
Figure US20150190322A1-20150709-C00021
wherein the dashed bonds represent a single or double bond, R and R′ are individually selected from the group consisting of hydrogen, a C1-C6 straight or branched chain alkyl, X is selected from the group consisting of a halide, a halide containing group or a hydrogen, y is 0 or 1, x is 0 or 1 and x and y are not both 1, or a salt thereof.
9. The method of claim 7, wherein the dermis includes an eyelid.
10. The method of claim 8, wherein the compound has the formula:
Figure US20150190322A1-20150709-C00022
11. The method of claim 8, wherein the compound has the formula:
Figure US20150190322A1-20150709-C00023
12. The method of claim 8, wherein the compound has the formula:
Figure US20150190322A1-20150709-C00024
13. The method of claim 8, wherein the compound has the formula:
Figure US20150190322A1-20150709-C00025
14. The method of claim 8, wherein the composition further comprises a dermatologically acceptable carrier.
15. A kit comprising:
a container;
a composition comprising a compound of the formula:
Figure US20150190322A1-20150709-C00026
wherein the dashed bonds represent a single or double bond; R and R′ are individually selected from the group consisting of hydrogen, a C1-C6 straight or branched chain alkyl; X is selected from the group consisting of a halide, a halide containing group or a hydrogen; y is 0 or 1, x is 0 or 1 and x and y are not both 1 or not both 0; or a pharmaceutically acceptable salt thereof, and
wherein the container includes an amount of the composition for repeated application over a period.
16. The kit of claim 15 further comprising an applicator.
17. The kit of claim 15, wherein the compound is selected from at least one of the following:
Figure US20150190322A1-20150709-C00027
US14/661,962 2009-02-03 2015-03-18 Composition, method and kit for enhancing hair Abandoned US20150190322A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/661,962 US20150190322A1 (en) 2009-02-03 2015-03-18 Composition, method and kit for enhancing hair

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14966109P 2009-02-03 2009-02-03
US12/698,823 US20110293549A1 (en) 2009-02-03 2010-02-02 Composition, method and kit for enhancing hair
US13/631,193 US9006291B2 (en) 2009-02-03 2012-09-28 Composition, method and kit for enhancing hair
US14/661,962 US20150190322A1 (en) 2009-02-03 2015-03-18 Composition, method and kit for enhancing hair

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/631,193 Division US9006291B2 (en) 2009-02-03 2012-09-28 Composition, method and kit for enhancing hair

Publications (1)

Publication Number Publication Date
US20150190322A1 true US20150190322A1 (en) 2015-07-09

Family

ID=45022312

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/698,823 Abandoned US20110293549A1 (en) 2009-02-03 2010-02-02 Composition, method and kit for enhancing hair
US13/631,193 Active US9006291B2 (en) 2009-02-03 2012-09-28 Composition, method and kit for enhancing hair
US14/661,962 Abandoned US20150190322A1 (en) 2009-02-03 2015-03-18 Composition, method and kit for enhancing hair

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US12/698,823 Abandoned US20110293549A1 (en) 2009-02-03 2010-02-02 Composition, method and kit for enhancing hair
US13/631,193 Active US9006291B2 (en) 2009-02-03 2012-09-28 Composition, method and kit for enhancing hair

Country Status (1)

Country Link
US (3) US20110293549A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110293549A1 (en) * 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US11744788B2 (en) * 2021-10-27 2023-09-05 James D. Welch Method of encouraging growth and regrowth of hair in human males technical area
FR3152224A1 (en) * 2023-08-22 2025-02-28 Doll Up Secret - Fzco Cosmetic composition intended for the treatment of eyelashes and eyebrows

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147823A1 (en) * 2002-02-04 2003-08-07 Allergan, Inc. Method of enhancing hair growth
US9006291B2 (en) * 2009-02-03 2015-04-14 Pharma Patent Holding Inc. Composition, method and kit for enhancing hair

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3382248A (en) 1965-11-01 1968-05-07 Upjohn Co 6-amino-4, 5-di(substituted amino)-1, 2-dihydro-1-hydroxy-2-iminopyrimidines
BE755555A (en) 1969-09-02 1971-03-01 Richardson Merrell Inc QUINOXALINE DERIVATIVES
US4304907A (en) 1972-05-10 1981-12-08 The Upjohn Company Bicyclo lactone intermediates for prostaglandin analogs
US3922297A (en) 1973-01-16 1975-11-25 Upjohn Co Prostaglandin E{HD 1{B , F{HD 1{B , and A{HD 1 {B analogs
FR2400895A1 (en) 1974-01-31 1979-03-23 Aries Robert 10-Fluoro or 12-fluoro-prostaglandin derivs. - and lactone precursors, useful in human or veterinary medicine
US3931282A (en) 1974-02-21 1976-01-06 Syntex (U.S.A.) Inc. 11α-Hydroxymethyl prostaglandins
US4217360A (en) 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
DE2517771A1 (en) 1975-04-18 1976-10-28 Schering Ag NEW PROSTAGLANDIN ACETYLENE ANALOGS AND METHOD FOR THEIR PRODUCTION
ES449162A1 (en) 1975-06-23 1977-12-16 Syntex Inc A PROCEDURE FOR THE PREPARATION OF A RACEMI-CO U 8R-ANTIMERIC COMPOUND.
US4005133A (en) 1975-10-14 1977-01-25 The Upjohn Company PGF2.sub.α, L-Arginine salt
US4139619A (en) 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4178457A (en) 1978-07-10 1979-12-11 Syntex (U.S.A.) Inc. (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof
JPS6032718Y2 (en) 1981-06-10 1985-09-30 松下電工株式会社 Alarm input control circuit using integrated circuit for speech synthesis
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
JPS59227888A (en) 1983-06-10 1984-12-21 Asahi Glass Co Ltd Production of 7-fluoroprostaglandin
US4912235A (en) 1983-12-22 1990-03-27 Syntex (U.S.A.) Inc. Processes and intermediates for making 16-phenoxy- and 16-substituted phenoxy-prostatrienoic acid derivatives and their stereoisomers
JPS6134778U (en) 1984-07-31 1986-03-03 株式会社明電舎 electrical equipment storage box
JPS61218510A (en) 1985-03-22 1986-09-29 Dai Ichi Seiyaku Co Ltd Agent for hair
US4889845A (en) 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
GB2209939B (en) 1987-09-18 1992-01-02 R Tech Ueno Ltd The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ATE101342T1 (en) 1988-09-06 1994-02-15 Kabi Pharmacia Ab PROSTAGLAND INDIVIDUALS FOR THE TREATMENT OF GREEN STAR OR OCULAR HYPERTENSION.
US5321128A (en) 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US4968812A (en) 1989-06-23 1990-11-06 Shell Oil Company Spirolactonelactams
SE9002596D0 (en) 1990-08-08 1990-08-08 Pharmacia Ab A METHOD OF SYNTHESIS OF PROSTAGLANDIN DERIVATIVES
US5288754A (en) 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
JP3102141B2 (en) 1992-05-29 2000-10-23 東レ株式会社 Hair restorer
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
JP3083925B2 (en) 1992-11-24 2000-09-04 ティーディーケイ株式会社 Electronic component mounting method and device
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5387608A (en) 1993-08-17 1995-02-07 Allergan, Inc. Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents
US6323204B1 (en) 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
SE9303444D0 (en) 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
US5545665A (en) 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5516796A (en) 1994-03-24 1996-05-14 Kabi Pharmacia Ab Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
AU722303C (en) 1996-03-05 2001-12-06 Robert Gurny Pharmaceutical compositions containing buffered ortho ester polymers
AU729318B2 (en) 1996-05-28 2001-02-01 Allergan, Inc. Cyclopentan(en)e heptenoic acid, 2-alkenyl derivatives as therapeutic agents in the treatment of ocular hypertension
DK0857718T3 (en) 1996-06-10 2002-12-16 Sucampo Ag endothelin antagonist
ATE221048T1 (en) 1996-09-17 2002-08-15 Asahi Glass Co Ltd FLUORINATED PROSTAGLAND DERIVATIVES AND MEDICATIONS
JPH1087607A (en) 1996-09-17 1998-04-07 Asahi Glass Co Ltd Method for producing fluorine-containing prostaglandin derivative
JP3480549B2 (en) 1996-12-26 2003-12-22 参天製薬株式会社 Difluoroprostaglandin derivatives and uses thereof
ATE266397T1 (en) 1997-02-04 2004-05-15 Murray A Johnstone METHOD FOR PROMOTING HAIR GROWTH AND DEVELOPMENT OF THE HAIR SYSTEM
EP0925787A4 (en) 1997-02-27 1999-12-01 Toray Industries Drugs for ameliorating pulmonary circulation
JP3217293B2 (en) 1997-04-17 2001-10-09 株式会社アールテック・ウエノ Hair growth / hair restorer
AU9305898A (en) 1997-09-09 1999-03-29 Procter & Gamble Company, The A process for making prostaglandin f analogs
IL134792A0 (en) 1997-09-09 2001-04-30 Procter & Gamble Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
HUP0004427A3 (en) 1997-09-09 2001-09-28 Procter & Gamble Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
DE69824966T2 (en) 1997-09-09 2005-04-07 Duke University AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO-PROSTAGLANDINE USES AS FP AGONISTE
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
JP2002509916A (en) 1998-03-31 2002-04-02 ザ プロクター アンド ギャンブル カンパニー C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists
US6444840B1 (en) 1998-03-31 2002-09-03 The Procter & Gamble Co. C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists
AU749796B2 (en) 1998-03-31 2002-07-04 Duke University C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
EP1115406A4 (en) 1998-09-25 2003-03-05 Alcon Lab Inc SUSTAINABLE RELEASE OPHTHALMIC COMPOSITION AND METHOD OF EYE THERAPY
MXPA01008956A (en) 1999-03-05 2002-04-24 Procter & Gamble C16.
CA2364948C (en) 1999-03-05 2011-04-26 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
IL147771A0 (en) 1999-08-04 2002-08-14 Procter & Gamble Novel 2-decarboxy-2-phosphinico prostaglandin f analogs
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020146439A1 (en) 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
KR100757656B1 (en) 2000-07-14 2007-09-10 알레간 인코포레이티드 Compositions Containing Alpha 2-Adrenergic Agonist Components
FR2812193B1 (en) 2000-07-28 2003-10-24 Oreal USE OF AN ANTAGONIST OF PROSTAGLANDIN EP-2 AND / OR EP-4 RECEPTORS TO ATTENUATE, DECREASE OR STOP HAIR AND HAIR GROWTH IN COSMETIC PREPARATIONS
FR2812191B1 (en) 2000-07-28 2003-10-17 Oreal USE OF PROSTAGLANDIN E2 RECEPTOR AGONISTS (EP-3) TO ATTENUATE, DECREASE OR STOP HAIR AND HAIR GROWTH IN COSMETIC PREPARATIONS
US6407250B1 (en) 2000-09-14 2002-06-18 Allergan Sales, Inc. Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
US6369089B1 (en) 2000-09-14 2002-04-09 Allergan Sales, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
US6511999B2 (en) 2000-09-14 2003-01-28 Allergan, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
US6248783B1 (en) 2000-09-20 2001-06-19 Allergan Sales, Inc. Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
US6291522B1 (en) 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US7060297B2 (en) 2000-11-06 2006-06-13 Alcon, Inc. Carrageenan viscoelastics for ocular surgery
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
PL202778B1 (en) 2001-02-22 2009-07-31 Skyepharma Canada Inc Fibrate-statin combinations with reduced fed-fasted effects
US6410591B1 (en) 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US6531504B2 (en) 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
US6476064B1 (en) 2001-06-13 2002-11-05 Allergan, Inc. Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents
US20030027853A1 (en) 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US6713268B2 (en) 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
US6743439B1 (en) 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
EP1298223A3 (en) 2001-09-28 2003-07-23 Pfizer Products Inc. Methods related to the A-C repeat Z-sequence upstream from the aldose reductase gene
CN1617868A (en) 2001-11-05 2005-05-18 阿勒根公司 Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
SE0104334D0 (en) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
US20040082013A1 (en) 2002-01-24 2004-04-29 Regan John W Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2alpha activity and methods of treating cancer
JP2005531516A (en) 2002-03-18 2005-10-20 ファイザー・プロダクツ・インク Method of treatment with selective EP4 receptor agonist
GB0208785D0 (en) 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
JP2003321442A (en) 2002-04-24 2003-11-11 Santen Pharmaceut Co Ltd Novel difluoroprostaglandin amide derivatives
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
US20030199590A1 (en) 2002-07-25 2003-10-23 Cagle Gerald D Prostaglandin analogues for promotion of hair growth
US6864282B2 (en) 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
MXPA05002259A (en) 2002-08-30 2005-07-05 Alcon Inc Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
US6875787B2 (en) 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
TWI336257B (en) 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
JP4860475B2 (en) 2003-06-13 2012-01-25 アルコン，インコーポレイテッド Ophthalmic composition comprising a synergistic combination of two polymers
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7015243B2 (en) 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
US7045634B2 (en) 2003-09-05 2006-05-16 Allergan, Inc. Prostamide receptor antagonists
US20050058614A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
US7070768B2 (en) 2003-09-25 2006-07-04 Allergan, Inc. Method for imparting artificial tan to human skin
US7186744B2 (en) 2003-11-13 2007-03-06 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
US20050112075A1 (en) 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US6989445B2 (en) 2003-12-15 2006-01-24 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
JP2007534699A (en) 2004-04-26 2007-11-29 アルコン，インコーポレイティド Statins for the treatment of ocular hypertension and glaucoma
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7183310B2 (en) 2004-08-10 2007-02-27 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101906B2 (en) 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US20060154981A1 (en) 2005-01-12 2006-07-13 Alcon, Inc. Method of reducing intraocular pressure and treating glaucoma
GB0506759D0 (en) 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
EP1917239A1 (en) 2005-06-29 2008-05-07 Pfizer, Inc. Fluoroprostaglandins nitroderivatives
US7879910B1 (en) 2006-10-10 2011-02-01 Jan Marini Skin Research, Inc. Compositions and methods for promoting lush hair growth
US7868032B2 (en) 2006-10-18 2011-01-11 Allergan, Inc. Prostamide receptor antagonists
AU2009287650B2 (en) 2008-09-04 2014-11-13 AGC Inc. Hair growth promoting agent containing 15,15 -difluoroprostaglandin F2alpha derivative as active ingredient
EP2349242B1 (en) 2008-10-29 2018-12-05 Novaer Holdings, Inc. Amino acid salts of prostaglandins
WO2010108012A1 (en) 2009-03-18 2010-09-23 Duke University Compositions and methods for promoting nasal patency and treating neurogenic bladder using prostaglandins
JP5331025B2 (en) 2010-02-18 2013-10-30 八千代工業株式会社 Sunroof device guide pipe holding structure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147823A1 (en) * 2002-02-04 2003-08-07 Allergan, Inc. Method of enhancing hair growth
US9006291B2 (en) * 2009-02-03 2015-04-14 Pharma Patent Holding Inc. Composition, method and kit for enhancing hair

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jean-Pierre Begue & Daniele Bonnet-Delpon, Recent Advances (1995-2005) in Fluorinated Pharmaceutical Based on Natural Products, 127 J FLUOR. CHEM. 992 (2006) *

Also Published As

Publication number Publication date
US9006291B2 (en) 2015-04-14
US20130046024A1 (en) 2013-02-21
US20110293549A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
US20090018204A1 (en) Composition and method for enhancing hair growth
AU2003207843B2 (en) Method of enhancing hair growth
EP3062797B1 (en) Compositions for reducing hair loss and/or increasing hair regrowth
US20230355497A1 (en) Compositions for reducing hair loss and/or increasing hair regrowth
US20130011354A1 (en) Compositions For Enhancing Hair Growth
US20150190322A1 (en) Composition, method and kit for enhancing hair
US8859616B2 (en) Compounds and methods for enhancing hair growth
EP2600825B1 (en) Method for curling hair
US20100305047A1 (en) Cyclosporin derivatives for enhancing the growth of hair
JP6188837B2 (en) Non-therapeutic hair curl method
HK1181669B (en) Composition, method and kit for enhancing hair
HK1181669A (en) Composition, method and kit for enhancing hair
AU2012261499B2 (en) Method of enhancing hair growth
AU2012207093A1 (en) Compounds and methods for enhancing hair growth

Legal Events

Date Code Title Description
AS Assignment

Owner name: AC PATENT HOLDING INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:PHARMA PATENT HOLDING INC.;REEL/FRAME:036325/0187

Effective date: 20150623

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION